ClinicalTrials.gg
Not yet recruitingNCT05220800NAIDICUpdated Mar 3, 2022

Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer

A Phase 2 interventional study of Iron(III)isomaltoside and Placebo in Iron-deficiency and Colorectal Cancer, sponsored by Zealand University Hospital. Not yet recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Zealand University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Anemia, Iron-Deficiency with a site in Denmark — 1 open to participants now, 1 under way, none of them phase 3. Anemia, Iron-Deficiency · Denmark.

Started
2022
with 1 other
Phase 2
Only one
of the 12
Registered
10th of 12
by date
Lead sponsor
1 of 12
Zealand University Hospital

Among the 12 studies in Anemia, Iron-Deficiency with a site in Denmark, this one is one of 2 that started in 2022, is the only one in phase 2, and was the 10th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

1 of the 12 studies in Anemia, Iron-Deficiency with a site in Denmark is open now.

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Anemia, Iron-Deficiency with a site in Denmark, or all of them as a file.
02

Study summary

This double-blinded clinical randomized trial with a 1:1 recruitment ratio between placebo and the active group will aim to investigate the effects of intravenously administered iron in non-anemic iron deficient patients on physical capacity, immunological cells and their function prior to surgery. A total of 134 patients with colorectalcancer will be included in the study.

Study outline:

After initial inclusion the patient will undergo baseline testing with cardiopulmonary exercise test (CPET), then followed by an infusion of a weight dependent dosage of iron(III)isomaltoside or placebo. Then at the closest possible time to the surgery the patient will have drawn bloodwork and be re-tested by (CPET). The patient will be followed after surgery with evaluation of several outcomes including quality of recovery and complications. Further, the effects of the intervention on the patients immune function will be evaluated by two different methods: 1) by changes in neutrophil-to-lymphocyte ratio between baseline and preoperative bloodwork and 2) by evaluation mRNA expression in the tumor specimen by the Nanostring pancancer immune panel

Read the detailed description

Aim The aim is to investigate the effects of intravenously administered iron in non-anemic iron deficient patients on physical capacity, immunological cells and their function prior to surgery.

Study design The study will be performed as a double-blinded clinical randomized trial with a 1:1 recruitment ratio between placebo and the active group. The study will be performed as a multicenter study with inclusion at Department of Surgery, Zealand University Hospital, Departement of Surgery, Slagelse Hospital and Department of Surgery, Regionshospital Randers. The study will need 134 participants, 67 in each arm.

Potential patients will be identified through routine blood samples taken prior to the first consultation. The samples will contain a complete anemia workup and a white blood cell count. The clinical guidelines for identifying and treating anemia in patients with colorectal cancer prior to surgery defines anemia by a hemoglobin ≤ 7 mmol/L for both men and women. Therefore non-anemic patients are defined by a hemoglobin above 7 mmol/L for both men and women in this protocol. Patients, who consents to the study, will immediately after the consultation be randomized and given weight dependent dose of Monofer® (Iron(III)-Isomaltoside) or placebo. On the day prior to surgery (or closest possible time) blood samples similar to the previous samples, will be taken, but with two additional blood samples, which will be stored for later analysis.

At the day of surgery, samples from the invasive front of the removed tumor will be taken and stored for later analysis by the Nanostring PanCancer Immune panel.

The first 20 patients from the Zealand University Hospital and Slagelse hospital will be physical tested by CPET prior to randomization and the day prior to surgery.

All patients will receive the same standardized peri- and postoperative care. All clinical decisions will be at the surgeon's discretion. On the days after surgery until discharge, daily routine blood samples will be taken, including white blood cell count and an assessment of the recovery, through the validated and translated questionnaire Quality of Recovery-15 (QoR-15). Discharge will be handled through standardized discharge criteria. After thirty days after surgery the patient will be contacted by phone for a follow up, concerning complications after discharge and medical records scrutinized for postoperative events.

Randomization and allocation concealment Randomization to the intervention or placebo group will be handled through an online block randomization stratificatied by sex, center of treatment and hemoglobin levels at baseline. Hemoglobin levels at baseline will be divided into four groups: 7.1-8.0, 8.1-9.0, 9.1-10.0 and ≥10.1. Placebo or MonoFer (Iron(III)-Isomaltoside) will be administered through identical opaque bags. Placebo will be an isotonic saline solution. The randomization key will be stored online behind an encryption key (in EasyTrial), which only will be opened after all testing of primary outcomes have been concluded. In order to secure double blinding a specific procedure for administration will be performed outlined in figure 3. When randomization are performed the randomization ID will have a corresponding closed cardboard box with a label with the randomization ID. The box will contain everything needed for concealment, equipment for intravenous administration, isotonic saline solution, and if active also 1000 mg (maximum dosage) MonoFer (Iron(III)-Isomaltoside). The box will be delivered to a clinical nurse which will mix the drug and put it into the opaque bag. A project nurse will secure an intravenous catheter, tape the catheter with opaque tape, put the patients hand through a curtain and leave the room. The clinical nurse will then administer the drug/placebo behind the curtain. The project nurse will do the observation of the patient during the infusion and the clinical nurse will remove the drug/placebo after end infusion. The box will be packed by the Central Pharmacy of Region Zealand and delivered to each site. All clinical nurses will receive training prior to initiation of the study in regards to proper mixing and concealment procedure.

Trial medication, packaging, labeling and administration The trial medication in use for this trial is weight depended MonoFer (Iron(III)isomaltoside 100 mg/ml) versus placebo which is isotonic saline, as an one-time dosage administered intravenously in hospital. The weight depended dosages are as follows: \<50 kg bodyweight: 500 mg, 50-59 kg bodyweight: 600 mg, 60-69 kg bodyweight: 700 mg, 70-79 kg bodyweight: 800 mg, 80-89 kg bodyweight: 900 mg, and ≥90 kg bodyweight 1000 mg Monofer. MonoFer needs to be mixed with isotonic saline just prior to administration. Thus, in order to secure proper concealment everything needing for mixing and administration are packed in closed cardboard boxes. The boxes are labelled in concordance with The Rules Governing Medicinal Products in the European Union Directive 2003/94/EC

Each cardboard box will contain 500 ml isotonic saline infusion fluid, a drop line and an opaque bag which will cover both the line and the fluid, labeling for the opaque bag, and a standard operating procedure document detailing handling and allocation concealment procedure (appendix II: Håndtering af forsøgsmedicin). If allocated to the active group the box will also contain 10ml MonoFer 100mg/ml.

If the administration are interrupted before the full dosage are administered the actual dosage given are noted by the clinical nurse and passed on to the project nurse which will secure the registration without deblinding the patient or research staff. Otherwise the full dosage of 500 ml will be recorded.

The infusion will be stopped if the patient experiences any adverse effects during the infusion. A particular reaction called a 'Fishbane reaction' in which the patient develops reddening of the skin, especially in the face, and truncal myalgia, but without any other symptoms of an allergic reaction will not be cause termination of the infusion. The Fishbane reaction is always selflimitating and is not associated with respiratory stridor, edema, hypotension or tachycardia. In case of a Fishbane reaction the infusion is stopped until the symptoms have dissipated, then the infusion is restarted, but with double the infusion time. If the Fishbane reaction reoccurs the infusion is terminated and dosage given registered.

Definition of per protocol Patients are considered per protocol if the patient received full dosage of placebo or MonoFer, and underwent surgery for a malignant tumor.

03

Conditions studied

  • Iron-deficiency
  • Colorectal Cancer

Keywords

  • surgery
  • Iron-deficiency
  • Colorectal cancer
  • Intravenous iron
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned for curative intended elective colon or rectum cancer surgery
  • UICC stage I-III (at diagnosis)
  • > 7.0 mmol/L
  • Serum ferritin \<101 microgram/L or transferrin saturation \<21%

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney failure with need for dialysis
  • Metachronous diagnosed cancer
  • Unable to speak or understand Danish
  • Cognitive impairment e.g. moderate to severe dementia
  • Concurrent severe active bacterial infection
  • Known allergy for Iron(III)isomaltoside
  • for intravenous iron (Pofryria, livercirrosis, active hepatitis, transaminases three times the upper limit, hemosiderosis and hemochromatosis)
  • Withdrawal of
  • chemo or radiation therapy
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Iron(III)isomaltoside 1000

    Weight-dependent one-time dosage of intravenous administration of iron(III)isomaltoside given prior to surgery. Dosage: \<50 kg body weight = 500 mg, 50-59 kg body weight = 600 mg, 60-59 kg body weight = 700 mg, 70-79 kg body weight = 800 mg, 80-89 kg body weight = 900 mg, and 90+ kg body weight = 1000 mg.

    Drug: Iron(III)isomaltoside

  • Placebo comparator
    Placebo

    500 ml isotonic saline infusion fluid

    Drug: Placebo

Interventions

  • DrugIron(III)isomaltoside

    Weight-dependent dosage of iron(III)isomaltoside. See group descriptions

  • DrugPlacebo

    Isoton saline infusion

06

What researchers measure

Primary outcomes

  1. Change in oxygen uptake at the anaerobic threshold

    Change in oxygen uptake at the anaerobic threshold measured by cardiopulmonary exercise test before infusion and the days before surgery

    Time frame: at baseline and 1-4 days before surgery

  2. Change in neutrophile to lymphocyte ratio (NLR)

    Change in neutrophile to lymphocyte ratio (NLR) between baseline bloodwork and prior to surgery.

    Time frame: at baseline and 1-4 days before surgery

  3. Changes in T-cell function - mRNA expression analysis

    Nanostring pancancer immune analysis of tumor samples

    Time frame: 1 day after surgery

Secondary outcomes

  1. Quality of Recovery 15 (QoR-15)

    Questionaire Quality of Recovery 15 (QoR-15). Scale of 15 questions regarding surgical recovery. Each item with a maximum score of 10 and minimum of 0. Total maximum score 150. Lowest 0. The higher score the better recovery

    Time frame: Up to 7 days after surgery

  2. Complications

    Postoperative complications graded by the Clavien-Dindo classification and the comprehensive complication index

    Time frame: 30-days after surgery

  3. Days alive and out of hospital - 30

    Days alive and out of hospital 30 days after surgery

    Time frame: 30 days after surgery

  4. 1 year cancer free survival

    1 year cancer free survival. Either death or recurrence

    Time frame: 1 year after surgery

  5. 5 year cancer free survival

    5 year cancer free survival. Either death or recurrence

    Time frame: 5 years after surgery

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2022; primary completion for Mar 2024, 24 months later.

Of 16 phase 2 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2022
First posted
Feb 2, 2022
StartEst.
Mar 1, 2022
Primary completionEst.
Mar 1, 2024
CompletionEst.
Mar 1, 2029
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05220800
Collaborators
Randers Regional Hospital, Slagelse Hospital
Responsible party
Sponsor
First posted
Feb 2, 2022
Start date
Mar 1, 2022 (estimated)
Primary completion
Mar 1, 2024 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Mar 3, 2022

Study contacts

Rasmus Dahlin Bojesen, Ph.d., MD.
Contact
radb@regionsjaelland.dk
+4526193789

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion